The company claims it is "India's first vaccine candidate for COVID-19, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)".
The trials are among many across the world - there are around 120 vaccine programmes under way. The whole process of phase I and II should take another three to four months and the vaccine could be out in around four to five months, if all goes well.
India's drug control authorities have allowed Bharat Biotech to hold Phase 1 and 2 of clinical human trials after "company submitted results generated from preclinical studies, demonstrating safety and immune response", a statement issued by the firm added.
China's military received the approval to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said on Monday.
Interestingly, Bharat Biotech is in collaboration with a University of Wisconsin in the development of another Vaccine too.
CNBG has multiple experimental coronavirus vaccine candidates, and at least one of the drugs cleared Phase 2 of human trials successfully. "CoroFlu could be in human clinical trials by the fall of 2020".
Bharat Biotech said it accelerated objective in completing the comprehensive pre-clinical trials, which were expedited through national regulatory protocols. "The proactive support and guidance from CDSCO have enabled approvals to this project", Krishna Ella, Chairman and MD of Bharat Biotech told the Indian Express.
India is among the largest manufacturer of generic drugs and vaccines in the world. The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad. Both the federal government and the Quebec government have contributed funds towards the vaccine's development.
The company is also involved in the development of CoroFlu, a nasal vaccine for COVID-19, as part of an global collaboration of virologists at the University of Wisconsin-Madison and vaccine firm FluGen.
As the world deals with the novel coronavirus pandemic, China National Biotec Group (CNBG) has announced a major milestone in the effort to develop a vaccine for the deadly respiratory disease.
According to the Ministry of Health and Family Welfare, the total COVID infections spiked to 548,318, as on June 30.